Compile Data Set for Download or QSAR
Report error Found 222 Enz. Inhib. hit(s) with all data for entry = 9356
TargetNeprilysin(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM459216(US10759813, Example 1-B)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/19/2021
Entry Details
Go to US Patent

TargetNeprilysin(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM459217(US10759813, Example 2-C)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/19/2021
Entry Details
Go to US Patent

TargetNeprilysin(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM459218(US10759813, Example 2-D)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/19/2021
Entry Details
Go to US Patent

TargetNeprilysin(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM459219(US10759813, Example 3-C | US10759813, Example 3-D)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/19/2021
Entry Details
Go to US Patent

TargetNeprilysin(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM459221(US10759813, Example 4-B)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/19/2021
Entry Details
Go to US Patent

TargetNeprilysin(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM459222(US10759813, Example 5-B)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/19/2021
Entry Details
Go to US Patent

TargetNeprilysin(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM459223(US10759813, Example 6-B)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/19/2021
Entry Details
Go to US Patent

TargetNeprilysin(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM459224(US10759813, Example 7-B)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/19/2021
Entry Details
Go to US Patent

TargetNeprilysin(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM459225(US10759813, Example 8-B)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/19/2021
Entry Details
Go to US Patent

TargetNeprilysin(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM459228(US10759813, Example 10-3)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/19/2021
Entry Details
Go to US Patent

TargetNeprilysin(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM459245(US10759813, Example 11-13)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/19/2021
Entry Details
Go to US Patent

TargetNeprilysin(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM459250(US10759813, Example 12-4)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/19/2021
Entry Details
Go to US Patent

TargetNeprilysin(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM459251(US10759813, Example 12-5)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/19/2021
Entry Details
Go to US Patent

TargetNeprilysin(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM459252(US10759813, Example 12-6)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/19/2021
Entry Details
Go to US Patent

TargetNeprilysin(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM459253(US10759813, Example 12-7)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/19/2021
Entry Details
Go to US Patent

TargetNeprilysin(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM459254(US10759813, Example 12-8)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/19/2021
Entry Details
Go to US Patent

TargetNeprilysin(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM459255(US10759813, Example 12-9)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/19/2021
Entry Details
Go to US Patent

TargetNeprilysin(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM459257(US10759813, Example 12-11)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/19/2021
Entry Details
Go to US Patent

TargetNeprilysin(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM459259(US10759813, Example 12-13)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/19/2021
Entry Details
Go to US Patent

TargetNeprilysin(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM459262(US10759813, Example 12-16)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/19/2021
Entry Details
Go to US Patent

TargetNeprilysin(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM459267(US10759813, Example 12-21)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/19/2021
Entry Details
Go to US Patent

TargetNeprilysin(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM459268(US10759813, Example 12-22)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/19/2021
Entry Details
Go to US Patent

TargetNeprilysin(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM459273(US10759813, Example 12-27)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/19/2021
Entry Details
Go to US Patent

TargetNeprilysin(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM459285(US10759813, Example 15-5)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/19/2021
Entry Details
Go to US Patent

TargetNeprilysin(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM459300(US10759813, Example 15-21)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/19/2021
Entry Details
Go to US Patent

TargetNeprilysin(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM459304(US10759813, Example 15-25)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/19/2021
Entry Details
Go to US Patent

TargetNeprilysin(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM459305(US10759813, Example 15-26)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/19/2021
Entry Details
Go to US Patent

TargetNeprilysin(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM459306(US10759813, Example 15-27)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/19/2021
Entry Details
Go to US Patent

TargetNeprilysin(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM459307(US10759813, Example 15-28)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/19/2021
Entry Details
Go to US Patent

TargetNeprilysin(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM459308(US10759813, Example 15-30)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/19/2021
Entry Details
Go to US Patent

TargetNeprilysin(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM459311(US10759813, Example 15-33)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/19/2021
Entry Details
Go to US Patent

TargetNeprilysin(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM459313(US10759813, Example 15-35)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/19/2021
Entry Details
Go to US Patent

TargetNeprilysin(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM459319(US10759813, Example 15-42)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/19/2021
Entry Details
Go to US Patent

TargetNeprilysin(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM459321(US10759813, Example 15-46)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/19/2021
Entry Details
Go to US Patent

TargetNeprilysin(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM459322(US10759813, Example 15-48)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/19/2021
Entry Details
Go to US Patent

TargetNeprilysin(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM459327(US10759813, Example 15-57)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/19/2021
Entry Details
Go to US Patent

TargetNeprilysin(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM459329(US10759813, Example 15-60)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/19/2021
Entry Details
Go to US Patent

TargetNeprilysin(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM459330(US10759813, Example 15-61)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/19/2021
Entry Details
Go to US Patent

TargetNeprilysin(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM459331(US10759813, Example 15-63)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/19/2021
Entry Details
Go to US Patent

TargetNeprilysin(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM459333(US10759813, Example 15-67)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/19/2021
Entry Details
Go to US Patent

TargetNeprilysin(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM459343(US10759813, Example 15-79)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/19/2021
Entry Details
Go to US Patent

TargetNeprilysin(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM459344(US10759813, Example 15-80)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/19/2021
Entry Details
Go to US Patent

TargetNeprilysin(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM459347(US10759813, Example 15-83)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/19/2021
Entry Details
Go to US Patent

TargetNeprilysin(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM459348(US10759813, Example 15-84)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/19/2021
Entry Details
Go to US Patent

TargetNeprilysin(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM459349(US10759813, Example 15-86)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/19/2021
Entry Details
Go to US Patent

TargetNeprilysin(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM459350(US10759813, Example 15-89)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/19/2021
Entry Details
Go to US Patent

TargetNeprilysin(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM459351(US10759813, Example 15-90)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/19/2021
Entry Details
Go to US Patent

TargetNeprilysin(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM459357(US10759813, Example 15-96)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/19/2021
Entry Details
Go to US Patent

TargetNeprilysin(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM459360(US10759813, Example 15-102)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/19/2021
Entry Details
Go to US Patent

TargetNeprilysin(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM459365(US10759813, Example 15-111)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/19/2021
Entry Details
Go to US Patent

Displayed 1 to 50 (of 222 total ) | Next | Last >>
Jump to: